Dr. Clay Siegall, The Innovative Leader and CEO of Seattle Genetics
The CEO and Co-founder of Seattle Genetics, Dr. Clay Siegall, recently sat down for an interview with Inspirery. Seattle Genetics is a biotech firm whose specialty is developing drugs to help combat fatal diseases like cancer where there has not been a significant drug improvement for decades. Dr. Siegall who holds a Ph.D. in Genetics from George Washington University and a B.S. Degree in Zoology from the University of Maryland stated in his interview with Inspirery that he has always had an interest in medicine and the use of technology.
This interest led him to fulfill a desire of becoming his own boss, by taking control of his own patents, products, and developments. During his interview with Inspirery, he goes on to give a very personal account of a time when he witnessed a family member go through brutal chemotherapy treatment, that left him thinking about a better way to help patients with cancer. This desire led him to co-found Seattle Genetics. Through Dr. Siegall leadership, Seattle Genetics has grown into a major authority in the cancer research field. As a scientist and leader of the company, Dr. Siegall’s team is at the forefront of developing antibody-drug conjugates (ADC).
Dr. Clay Siegall had a very illustrious career at Bristol-Myers Squibb Pharmaceutical Research Institute before starting his own successful company, and before that, he was with the National Institutes of Health and National Cancer Institute. Currently, he holds 15 patents to his name and is the author of over 70 publications. While this is impressive, it is not surprising when it comes to Dr. Siegall.
Dr. Siegall’s desire to help find a cure for cancer and to treat patients in a less brutal way when going through chemotherapy has led him to form a company that will be innovative for decades to come, if not for centuries. Leading the fight to improve the mortality rate of individuals has placed Seattle Genetics at the leaderboard and Dr. Siegall as CEO and co-founder in the driver seat of this research and drug development team.